SARM MK-0773 Female Sarcopenia 6-Month RCT — Post-Menopausal Muscle via Drug. Hormone Target New Dimension
Post-menopausal women’s sarcopenia common but FDA approved drugs = 0. Exercise·protein are standard but clearly limited. Journal of Cachexia, Sarcopenia and Muscle Phase IIa RCT = Selective Androgen Receptor Modulator (SARM) MK-0773 proves muscle mass significant increase in 65+ women n=170 6-month trial. Sarcopenia drug era begins.
Key Announcement
MK-0773 Phase IIa RCT: Participants 65+ women n=170, period 6 months, drug MK-0773 (Merck SARM), vs placebo, results significant muscle mass increase (p<0.05), some strength improvement, good safety profile
FDA approved sarcopenia drugs: 0 (so far), exercise·protein·testosterone (L69 UConn) only, new target pipeline: myostatin·NAD+·senolytic
SARM
SARM (Selective Androgen Receptor Modulator): Androgen receptor target, tissue-specific selectivity (muscle·bone), ↓ side effects (prostate·liver·heart relatively safe), testosterone alternative
MK-0773 (Merck): Non-steroidal SARM, oral, muscle·bone selective, women·elderly trials
Post-Menopausal Sarcopenia - Blind Spot
Prevalence: 65+ women 25~50%, 80+ women 50%+, Korean elderly women estimated 2M+
Causes: Estrogen ↓ → muscle protein synthesis ↓, androgen ↓, activity ↓, protein intake ↓, chronic inflammation·insulin resistance
Clinical impact: Gait disorder·falls, fractures (hip·spine), hospitalization ↑, mortality ↑, quality of life ↓
MK-0773 Mechanism
Muscle·bone selective androgen receptor stimulation: Muscle protein synthesis ↑, protein breakdown ↓, bone density ↑, ↓ other tissue side effects
Suitable for women: Testosterone (L69 UConn) potent but side effects (masculinization·other hormones), SARM selective → ↑ safety, 6-month use safety proven
Clinical Data
Phase IIa results: DXA-measured muscle mass significant increase, partial leg strength improvement, partial gait speed improvement, good safety profile (no liver·heart·prostate impact)
Limits: Phase IIa = 170 (small scale), 6 months (long-term data limited), mortality·fracture outcomes not evaluated, Phase III needed
Sarcopenia Drug Pipeline - Global
SARM family: MK-0773 (Merck) — L72, Enobosarm (Veru), Ostarine (GTx, discontinued), LGD-4033
Myostatin inhibitors: Bimagrumab (Novartis, kidney disease·sarcopenia), anti-myostatin antibody
NAD+ boosters: NMN·NR (L59 Nature), supplements
Senolytic: L63 fisetin (TROFFi), L67 OS-01 body
Testosterone: L69 UConn STEP-HI (65+ women)
L72 Digital Verification·Establishment Dimension - 5th Axis
Women’s hormone·muscle·aging system new dimension (testosterone + SARM + GLP-1 + senolytic).
Korean Implications
Current Korea: Sarcopenia diagnosis (DXA·strength), exercise (resistance·aerobic), protein (1.0~1.5 g/kg/day), vitamin D, drugs absent
MK-0773 expected: Phase III → FDA approval, Korean MFDS 12 yr, 20282030 expected, price $400~$1,200/month (estimate)
Self-Assessment
SARC-F: 5 questions (strength·gait·rising·stairs·falls), 4+ = sarcopenia suspicion
Measurement: DXA (composition), grip strength (men <26 kg, women <18 kg), gait speed (<0.8 m/s), 5-time chair rise (>15 sec)
Daily Guide
Prevention·management (exercise·diet): Resistance exercise 23x/wk (essential), protein 1.01.5 g/kg/day, vitamin D 2,000~4,000 IU, leucine-rich protein (whey·eggs·meat), adequate sleep
Drugs (current): Testosterone (doctor prescription, ↑ side effects), non-hormonal: SARM (unapproved), myostatin inhibitor (trial)
Future (2028~): MK-0773 + exercise·protein integrated, precision decision (DXA·genetics·hormones)
Safety - Women SARM Considerations
SARM potential concerns: Liver enzymes (rare), cholesterol changes, masculinization (rare SARM), long-term safety data lacking
MK-0773 data: 6-month safety good, masculinization side effects not reported, Phase III precision evaluation
FAQ
Q. SARM not a doping drug? A. SARM WADA prohibited. But medical indication (sarcopenia) trials separate. MK-0773 = medical drug development.
Q. Exercise alone solves post-menopausal sarcopenia? A. Some yes. But many patient limits. SARM·testosterone drug supplements. Exercise·drug integration.
Q. SARM prescription in Korea? A. Unapproved. Some overseas direct purchase (doping·unregulated). Not medical recommended. Doctor consult after trial participation.
Q. SARM side effects scary? A. 6-month data good. Phase III precision evaluation. But unapproved doping SARM dangerous (liver·cholesterol·hormones).
Q. Future sarcopenia integrated care? A. Drug (SARM·testosterone·myostatin) + exercise + protein + senolytic + vitamin D + AI monitoring integrated.
Conclusion
SARM MK-0773 = women’s sarcopenia drug era entry. First clinical data for FDA-0-approved domain. L72 = 45 pillars + digital verification·establishment dimension (hormone·muscle 5th axis). Korea adoption 2028~2030. Exercise·protein·testosterone + SARM = post-menopausal women muscle recovery multi-axis matrix.